Abiomed says it’s enrolled the 1st patient in the RECOVER RIGHT trial of its Impella RP heart pump.

Abiomed (NSDQ:ABMD) said the 1st patient to receive its right-side heart pump, the Impella RP, as part of a clinical trial aimed at U.S. approval was implanted with the device in Philadelphia.

The Danvers, Mass.-based medical device company said the patient was implanted with the Impella RP after implantation with another type of heart pump called a left ventricular assist device, according to a press release. To be eligible for Abiomed’s 2-year, 30-patient Recover Right trial, patients must either develop right-side heart failure within 48 hours after LVAD implantation, after going into shock within 48 hours of heart surgery or a heart attack, the company said.